sumatriptan has been researched along with Itching in 3 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy." | 2.77 | Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012) |
| "Chloroquine was injected intradermally into the rostral back of NMRI mice, and the scratching behavior was evaluated by measuring the number of bouts over 30 min." | 1.48 | Pharmacological evidence of involvement of nitric oxide pathway in anti-pruritic effects of sumatriptan in chloroquine-induced scratching in mice. ( Afshari, K; Dehpour, AR; Foroutan, A; Haddadi, NS; Ostadhadi, S; Rahimi, N; Shakiba, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haddadi, NS | 2 |
| Ostadhadi, S | 2 |
| Shakiba, S | 2 |
| Afshari, K | 2 |
| Rahimi, N | 1 |
| Foroutan, A | 2 |
| Dehpour, AR | 2 |
| Daneshpazhooh, M | 1 |
| Smith, TR | 1 |
| Goldstein, J | 1 |
| Singer, R | 1 |
| Pugach, N | 1 |
| Silberstein, S | 1 |
| Pierce, MW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months[NCT00792103] | Phase 3 | 198 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Nausea free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 143 |
Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 105 |
Phonophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participants (Number) |
|---|---|
| NP101 | 109 |
Photophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours
| Intervention | participant (Number) |
|---|---|
| NP101 | 97 |
For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin). (NCT00792103)
Timeframe: 24 hours post patch activation
| Intervention | scores on a scale (Mean) |
|---|---|
| NP101 | 1.0 |
1 trial available for sumatriptan and Itching
| Article | Year |
|---|---|
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Female; Follow-Up Stu | 2012 |
2 other studies available for sumatriptan and Itching
| Article | Year |
|---|---|
Pharmacological evidence of involvement of nitric oxide pathway in anti-pruritic effects of sumatriptan in chloroquine-induced scratching in mice.
Topics: Animals; Antipruritics; Behavior, Animal; Chloroquine; Disease Models, Animal; Dose-Response Relatio | 2018 |
Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Humans; Injections, Intradermal; Male; M | 2018 |